The recent 510(k) clearance of the Vanquish™ Water Vapor Ablation System by the U.S. Food and Drug Administration marks an interesting development in the evolving field of focal therapy for prostate cancer. Developed by Francis Medical, the technology introduces a familiar energy source—water vapor—but applies it in a new oncologic context: the focal ablation of prostate tissue.
For urologic surgeons, this approval highlights a broader trend in prostate cancer management: the continued push toward minimally invasive, organ-preserving treatment strategies that aim to balance oncologic control with preservation of urinary and sexual function.
Water Vapor as an Ablative Energy Source
The Vanquish system delivers sterile water vapor transurethrally into targeted regions of the prostate. When the vapor condenses within tissue, it releases stored thermal energy, producing rapid cell death in the treatment zone. This mechanism is based on convective heat transfer, allowing steam to disperse through tissue planes before releasing energy during condensation.
Many urologists will recognize the underlying concept from therapies used in benign prostatic hyperplasia, particularly the Rezum System developed by Boston Scientific. Rezūm demonstrated that convective water vapor can reliably ablate prostate tissue while maintaining a relatively favorable safety profile. Vanquish builds on this concept but is designed specifically for oncologic tissue ablation, targeting localized prostate cancer rather than benign obstruction.
From a surgical standpoint, the familiarity of the transurethral approach may facilitate adoption. The procedure leverages instrumentation and visualization techniques already common in endoscopic urology, potentially lowering the learning curve compared with more technically demanding focal modalities.
Clinical Evidence and the VAPOR Trial Program
The FDA clearance was supported by data from the VAPOR clinical trial program, including the VAPOR 2 study, which evaluated water vapor ablation in men with localized intermediate-risk prostate cancer. Early results have suggested that the procedure is technically feasible and capable of producing localized tissue necrosis within targeted treatment zones.
While these early findings are encouraging, the key questions for surgeons will center on durability of oncologic control, retreatment rates, and long-term functional outcomes. As with other focal therapies, short-term feasibility data are only the first step; longer follow-up will ultimately determine where this technology fits in the treatment algorithm.
Where Vanquish Fits in the Focal Therapy Landscape
The emergence of Vanquish adds another option to a growing field of focal prostate cancer technologies. Current alternatives include:
- High-intensity focused ultrasound platforms such as the Ablatherm HIFU
- Irreversible electroporation delivered via the NanoKnife System
- MRI-guided transurethral ultrasound systems like the TULSA-PRO System
Each modality offers a different balance of imaging integration, precision, treatment time, and tissue effects. Steam-based therapy is conceptually appealing because it leverages the physics of phase change, allowing energy to distribute through tissue spaces rather than relying solely on conductive heating.
However, as with all focal therapies, patient selection will remain critical. Candidates are typically men with localized, clinically significant disease who fall somewhere between active surveillance and definitive whole-gland therapy. For these patients, the goal is often to achieve local cancer control while minimizing functional morbidity.
Looking Ahead
From a surgeon’s perspective, the FDA clearance of Vanquish represents another incremental step in the transition toward precision, lesion-directed prostate cancer treatment. The concept of using water vapor for tissue ablation is not new, but applying it to focal oncologic therapy introduces an intriguing addition to the therapeutic toolkit.
Whether Vanquish ultimately becomes widely adopted will depend on the quality of long-term clinical data, reproducibility across centers, and how it compares with other focal technologies already in practice. As more patients undergo treatment and follow-up data mature, the urology community will gain a clearer understanding of where steam-based ablation fits in the management of localized prostate cancer.
For now, the FDA clearance of Vanquish highlights a continuing shift in prostate cancer care—one that increasingly prioritizes targeted treatment, reduced invasiveness, and preservation of quality of life.
References
- U.S. Food and Drug Administration. 510(k) medical device clearance database.
- Francis Medical. Vanquish™ Water Vapor Ablation System product and company information.
- Clinical data from the VAPOR 2 trial evaluating focal water vapor ablation for localized prostate cancer.
- McVary KT, et al. Convective water vapor energy therapy for benign prostatic hyperplasia using the Rezum System. Journal of Urology.
- Valerio M, et al. Focal therapy in prostate cancer: the European Association of Urology position. European Urology.